Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06926621 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 13 to 15v12
  2. Study sites: 12 to 13v11
  3. Study sites: 11 to 12v10
  4. Primary and study completion dates: Jul 24, 2028 to Jan 30, 2029 Enrollment target: 36 to 44 · Secondary endpoints: 4 to 2v9 Show 2 more changesShow less
    • Enrollment target: 36 to 44
    • Secondary endpoints: 4 to 2

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 10 to 11v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 7 to 10v7
  2. Study sites: 6 to 7v6
  3. Study sites: 5 to 6v5
  4. Study sites: 4 to 5v4
  5. Study sites: 1 to 4v3
  6. Trial status: Not Yet Recruiting to Enrolling by Invitation Primary endpoint revised · Study sites: 0 to 1 · Start date changed from estimate of Apr 15, 2025 to Apr 28, 2025v2 Show 3 more changesShow less
    • Primary endpoint revised
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 15, 2025 to Apr 28, 2025

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Trial Details
NCT Number NCT06926621
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Myotonic Dystrophy Type 1 (DM1)
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov